<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6776">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00985829</url>
  </required_header>
  <id_info>
    <org_study_id>pdt bcc1</org_study_id>
    <nct_id>NCT00985829</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy of Photodynamic Therapy in Basal Cell Carcinoma</brief_title>
  <official_title>Evaluation of Efficacy of Photodynamic Therapy in Basal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <authority>Iran: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of pdt in treatment of bcc and factors
      that affect response rate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background and Aim: Basal cell carcinoma (BCC) is the most common skin cancer .Photodynamic
      therapy _as a novel , non-invasive therapeutic approach _may be considered a valuable
      strategy. This study was designed with the aim of the evaluation of efficacy of PDT in
      treatment of BCC and factors that may affect response rate.

      Materials and Methods: This was a clinical trial which was done on 28 BCCs. Patients were
      treated with ALA-PDT monthly for 1-6 sessions and evaluated for clinical response,cosmetic
      results and probable side effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clinical Response to Photodynamic Therapy</measure>
    <time_frame>immediately after termination of treatment course (with an average of 5 month after initiation of PDT)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Histologic Resolution of Lesion</measure>
    <time_frame>immediately after the terminaton of treatment course (with an average of 5 months after initiation of PDT)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Basal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>BCC, ALA-PDT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with histologically proven basal cell carcinoma who were candidates for treatment with ALA-PDT</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>photodynamic therapy</intervention_name>
    <description>treatment of bcc with 5_ALA cream 20% topical administration once monthly+ photodynamic therapy (red light) 120 j/cm2 once monthly</description>
    <arm_group_label>BCC, ALA-PDT</arm_group_label>
    <other_name>PDT 1200L Waldman Medizintechnik; Schwenningen, Germany</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven BCCs

        Exclusion Criteria:

          -  rodent ulcer

          -  morphea type

          -  ANA +

          -  history of photosensitivity or photodermatosis or ingestion of phototoxic drugs
             during last month

          -  pregnancy

          -  breast feeding

          -  age&lt; 18

          -  history of another therapeutic intervention for bcc during last 6 months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zohreh Tehranchi-nia, assist.prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skin Research Center</affiliation>
  </overall_official>
  <verification_date>November 2009</verification_date>
  <lastchanged_date>November 18, 2009</lastchanged_date>
  <firstreceived_date>September 26, 2009</firstreceived_date>
  <firstreceived_results_date>September 30, 2009</firstreceived_results_date>
  <responsible_party>
    <name_title>Zohreh Tehranchi-nia</name_title>
    <organization>assistant professor of dermatology Shaheed Beheshti Medical University</organization>
  </responsible_party>
  <keyword>basal cell carcinoma</keyword>
  <keyword>photodynamic therapy</keyword>
  <keyword>photo chemotherapy</keyword>
  <keyword>basal cell epithelioma</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>all patients with Histologically proven basal cell carcinoma (BCC) entered the study.</recruitment_details>
      <pre_assignment_details>Exclusion Criteria:
rodent ulcer morphea type positive anti nuclear antibody test history of photosensitivity or photodermatosis or ingestion of phototoxic drugs during last month pregnancy breast feeding age&lt; 18 history of another therapeutic intervention for bcc during last 6 months</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Aminolevulinic Acid-Photodynamic Therapy (ALA-PDT)</title>
          <description>Patients with histologically proven basal cell carcinoma who would receive ALA-PDT for their lesion(s)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aminolevulinic Acid-Photodynamic Therapy (ALA-PDT)</title>
          <description>Patients with histologically proven basal cell carcinoma who would receive ALA-PDT for their lesion(s)</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="28"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="59.1" spread="12.7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Response to Photodynamic Therapy</title>
        <description>categorized in 3 groups: complete response: there was no visible or palpable lesion; partial response: there was a visible or palpable lesion but the diameter of the lesion had reduced; no response: there was a visible or palpable lesion and the diameter of the lesion had not reduced</description>
        <time_frame>immediately after termination of treatment course (with an average of 5 month after initiation of PDT)</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Aminolevulinic Acid-Photodynamic Therapy (ALA-PDT)</title>
            <description>Patients with histologically proven basal cell carcinoma who were candidates for photodynamic therapy</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Clinical Response to Photodynamic Therapy</title>
            <description>categorized in 3 groups: complete response: there was no visible or palpable lesion; partial response: there was a visible or palpable lesion but the diameter of the lesion had reduced; no response: there was a visible or palpable lesion and the diameter of the lesion had not reduced</description>
            <units>lesions</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>complete response</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>partial response</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>no response</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Histologic Resolution of Lesion</title>
        <description>disappearance of the lesion in histologic examination</description>
        <time_frame>immediately after the terminaton of treatment course (with an average of 5 months after initiation of PDT)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>from those 9 lesions with clinically complete reponse , 3 lesions were biopsied and assessed histologically.</population>
        <group_list>
          <group group_id="O1">
            <title>Aminolevulinic Acid-Photodynamic Therapy (ALA-PDT)</title>
            <description>Patients with histologically proven basal cell carcinoma who would receive ALA-PDT for their lesion(s)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Histologic Resolution of Lesion</title>
            <description>disappearance of the lesion in histologic examination</description>
            <units>lesions</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>complete resolution in histologic examination</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>not complete resolution in histologic examination</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cosmetic Result</title>
        <description>excellent: no scarring, atrophy, or induration, slight or no redness or change in pigmentation compared to the adjacent skin; good: no scarring, atrophy, or induration, moderate redness or increase in pigmentation compared to the adjacent skin; moderate: slight to moderate scarring, atrophy, or induration; and poor: extensive scarring, atrophy, or induration</description>
        <time_frame>1 month after termination of treatment course (with an average of 6 months after initiation of PDT)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>cosmetic result was assessed among patients with complete response</population>
        <group_list>
          <group group_id="O1">
            <title>Aminolevulinic Acid-Photodynamic Therapy (ALA-PDT)</title>
            <description>Patients with histologically proven basal cell carcinoma who would receive ALA-PDT for their lesion(s)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cosmetic Result</title>
            <description>excellent: no scarring, atrophy, or induration, slight or no redness or change in pigmentation compared to the adjacent skin; good: no scarring, atrophy, or induration, moderate redness or increase in pigmentation compared to the adjacent skin; moderate: slight to moderate scarring, atrophy, or induration; and poor: extensive scarring, atrophy, or induration</description>
            <units>lesions</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>excellent</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>good</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>poor</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Location of Lesion</title>
        <time_frame>baseline</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Aminolevulinic Acid-Photodynamic Therapy (ALA-PDT)</title>
            <description>Patients with histologically proven basal cell carcinoma who were candidates for photodynamic therapy</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Location of Lesion</title>
            <units>lesions</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>scalp</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>face</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ear</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>BCC Type</title>
        <description>superficial BCC (sBCC); pigmented BCC(pBCC);nodular BCC (nBCC)</description>
        <time_frame>baseline</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Aminolevulinic Acid-Photodynamic Therapy (ALA-PDT)</title>
            <description>Patients with histologically proven basal cell carcinoma who were candidates for photodynamic therapy</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>BCC Type</title>
            <description>superficial BCC (sBCC); pigmented BCC(pBCC);nodular BCC (nBCC)</description>
            <units>lesions</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>nodular</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>pigmented</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>superficial</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Past Medical History of Radiotherapy</title>
        <description>past medical history of radiotherapy to the site of tumor before its appearance(for another reason)</description>
        <time_frame>baseline</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Aminolevulinic Acid-Photodynamic Therapy (ALA-PDT)</title>
            <description>Patients with histologically proven basal cell carcinoma who were candidates for photodynamic therapy</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Past Medical History of Radiotherapy</title>
            <description>past medical history of radiotherapy to the site of tumor before its appearance(for another reason)</description>
            <units>lesions</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>positive</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>negative</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Aminolevulinic Acid-Photodynamic Therapy (ALA-PDT)</title>
          <description>Patients with histologically proven basal cell carcinoma who would receive ALA-PDT for their lesion(s)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>SNOMED CT</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>local intolerable pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Zohreh Tehranchi-nia, assist. prof</name_or_title>
      <organization>skin research center</organization>
      <phone>+989121029415</phone>
      <email>zohreh_tehranchi@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
